The formation of amyloid fibrils is considered to be an important step in the aetiology of Alzheimer's disease and other amyloidoses. Fibril formation in vitro has been shown to depend on many different factors including modifications to the amino acid profile of fibrillogenic peptides and interactions with both large and small molecules of physiological significance. How these factors might contribute to amyloid fibril formation in vivo is not clear as very little is known about the promotion of fibril formation in undersaturated solutions of amyloidogenic peptides. We have used thioflavin T fluorescence and reverse phase high performance liquid chromatography to show that ATP. and in particular AIATP. promoted the formation of thioflavin T-reactive fibrils of beta amyloid and, an unrelated amyloidogenic peptide, amylin. Evidence is presented that induction of fibril formation followed the complexation of AlATP by one or more monomers of the respective peptide. However, the complex formed could not be identified directly and it is suggested that AIATP might be acting as a chaperone in the assembly of amyloid fibrils. The effect of AIATP was not mimicked by either AlADP or AlAMP. However, it was blocked by suramin, a P2 ATP receptor antagonist, and this has prompted us to speculate that the precursor proteins to beta amyloid and amylin may be substrates or receptors for ATP in vivo. (C) 2001 Elsevier Science B.V. All rights reserved.
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Bohrmann, B
Tjernberg, L
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Tjernberg, L
Kuner, P
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Kuner, P
Poli, S
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Poli, S
Levet-Trafit, B
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Levet-Trafit, B
Näslund, J
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Näslund, J
Richards, G
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Richards, G
Huber, W
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Huber, W
Döbeli, H
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Döbeli, H
Nordstedt, C
论文数: 0引用数: 0
h-index: 0
机构:
F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, SwitzerlandF Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Bohrmann, B
Tjernberg, L
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Tjernberg, L
Kuner, P
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Kuner, P
Poli, S
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Poli, S
Levet-Trafit, B
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Levet-Trafit, B
Näslund, J
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Näslund, J
Richards, G
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Richards, G
Huber, W
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Huber, W
Döbeli, H
论文数: 0引用数: 0
h-index: 0
机构:F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland
Döbeli, H
Nordstedt, C
论文数: 0引用数: 0
h-index: 0
机构:
F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, SwitzerlandF Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland